Major new phase in heart failure management
AHA 2015, Orlando, FL, USA
Video navigation menu
- Clinical benefit of conventional inhibitors of the renin-angiotensin system (RAS). 0:01
- The search for better ways to inhibit RAS. 0:32
- Effects of simultaneous inhibition of RAS and neprilysin by sacubitril-valsartan (LCZ696). 1:18
- Implications of the PARADIGM-HF trial for clinical practice. 2:25
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.